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Abstract Hyperplasia of transitional cell epithelium ad- 
jacent to human transitional cell carcinomas (TCC) is a 
common finding in pathology. This hyperplasia may be a 
precancerous aberration. Alternatively, it has been sug- 
gested that the hyperplasia is due to paracrine action of 
tumour-derived growth factors. In this study we tested 
the latter hypothesis using the mouse tumorigenic TCC 
cell line NUC-1. Transplantation f NUC-1 tumour cells 
into the urinary bladder submucosa of syngeneic mice in 
vivo induced hyperplasia of normal adjacent urothelium 
in all tested mice. Implantation of normal mouse bladder 
mucosa did not induce urothelial hyperplasia. In vitro, 
conditioned medium of NUC-1 cells induced the prolif- 
eration of the mouse urothelial cell line g/G, which 
closely resembles normal urothelial cells. This induction 
was inhibited by transforming growth factor fll (TGFfll). 
Similarly, TGFfll inhibited the fibroblast growth factor-1 
(FGF-1) and FGF-2 induced proliferation of g/G cells. 
Chemico-physical examination, bioassays with condi- 
tioned media, and RNA analysis of NUC- 1 cells revealed 
that these cells secreted a growth factor with FGF-like 
properties. These results indicate that epithelial hyper- 
plasia surrounding carcinomas is not necessarily a pre- 
cancerous aberration, but may result from direct para- 
crine action of tumour-derived growth factors. 
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Introduction 
Several morphological aberrations are frequently ob- 
served in the human epithelium lining the mucosa adja- 
cent to carcinomas. For example, epithelial hyperplasia 
represents a rather common finding in a variety of carci- 
nomas, like colon carcinomas [16, 19], oesophageal car- 
cinomas [4], and transitional cell carcinoma (TCC) of the 
urinary bladder [2, 11]. Its pathogenesis is not clear yet. 
Two hypotheses have been put forward. According to one 
hypothesis, the hyperplastic epithelium is a precancerous 
aberration, which can change into dysplasia nd finally to 
a carcinoma [11]. In the alternative hypothesis, hyperpla- 
sia does not represent a precancerous stage, but develops 
as a reaction to the tumour, possibly because of tumour- 
derived growth factors acting on the surrounding epitheli- 
um [19]. 
Several data suggest an important role for growth fac- 
tors in the process of tumour growth in affecting the pro- 
liferation or differentiation of both normal and tumour 
cells (reviewed by Aaronson [1]). Growth factors can be 
synthesized and secreted by both normal cells and tu- 
mour cells, and they regulate physiological cellular pro- 
cesses by an autocrine or paracrine pathway. Some 
growth factors are present in normal urine (epidermal 
growth factor (EGF)) [3]. In bladder tumours and in 
urine of patients with bladder tumours other growth fac- 
tors including transforming growth factor c~ (TGFc0 and 
fibroblast growth factors (FGFs), have been found [5, 6, 
10, 17]. These growth factors are known to affect the 
proliferation of both transformed and non-transformed 
urothelial cells in vitro [7, 14, 22]. 
Based on experimental work, Sekikawa et al. [19] 
suggested that hyperplasia of colonic mucosa adjacent to 
colon carcinoma could be due to tumour-derived growth 
factors. In this study we investigated whether hyperplasia 
of normal urothelial cells adjacent o TCC could be in- 
duced by TCC-derived growth factors through paracrine 
action. We first developed an in vivo model 1o demon- 
strate the effects in vivo of mouse bladder carcinoma on 
the surrounding urothelium, by transplanting a mouse 
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urothelial tumorigenic ell line, designated NUC-1 [7], 
into the submucosa of the urine bladder of syngeneic 
mice. Secondly, we determined, in an in vitro model, the 
presence of tumour-derived growth factors that could en- 
hance the growth or proliferation of normal mouse uro- 
thelial cells. We studied the NUC-1 cell l ine for the pres- 
ence of growth factors, and their effects on the non-tu- 
morigenic mouse urothelial cell l ine g/G resembling nor- 
mal mouse urothelial cells [7]. 
Materials and methods 
Culture media and supplements were purchased from Flow Labora- 
tories (Zwanenburg, NL) and Sigma (St. Louis, USA), respectively. 
Human FGF-2 and TGFc~ were obtained from Oncogene Science 
(Uniondale, USA), human FGF-1 from Boehringer (Almere, NL), 
and mouse EGF, endothelial cell-derived growth factor (ECGS), 
and fibronectin from Sigma. Human transforming growth factor fll 
(TGF]31) was either obtained from Sigma, or purified from outdated 
human platelets as described [23]. Tritiated thymidine was pur- 
chased from Amersham ('sHertogenbosch, NL). 
Mouse urothelial cell lines NUC-1 and g/G were developed as 
described previously [7]. These cells were cultured routinely in a 
1:1 mixture of Dulbecco's Modified Eagle's Medium (DMEM) 
and Ham's F10 medium, supplemented with 10% fetal calf serum 
(FCS), 10 gM HEPES buffer, 100 IU/ml penicillin, 100 gg/ml 
streptomycin, selenite, transferrin, and 5 gg/ml insulin (standard 
medium) [7]. Serum-free culture was done in standard medium 
without FCS, but further supplemented with 0.1% bovine serum 
albumin (BSA), putrescin, ethanolamine, spermin, and spermidin 
as described [7]. 
A431 carcinoma cells were obtained from Dr. R M. J. J. Berns 
(Dept. of Biochemistry, Daniel den Hoed Cancer Centre, Rotter- 
dam, NL). These cells were routinely cultured in RPMI 1640 me- 
dium, supplemented with 10 gM HEPES buffer, 10% FCS, 100 
IU/ml penicillin, and 100 gg/ml streptomycin. ML-CCL64 mink 
lung carcinoma cells were cultured routinely in DMEM, buffered 
with 25 mM BES (N,N-bis[2-hydroxy-ethyl]-2-aminoethane 
sulfonic acid), and supplemented with 5% FCS, streptomycin a d 
penicillin as outlined above. Fetal bovine heart endothelial 
(FBHE) cells were routinely cultured in DMEM, supplemented 
with 10% FCS. 
In transplantation studies NUC-1 cells were cultured under 
routine conditions to confluency. After extensive washing with 
phosphate buffered saline (PBS) pH 7.2, cells were trypsinized, 
washed with PBS again and injected (1xl06 cells in 100 gl PBS) 
subcutaneously in normal syngeneic mice. After 3 weeks, NUC-1 
tumours were excised and minced into 1 mm 3 pieces. One piece 
was transplanted into the submucosa of the bladder of syngeneic 
mice via a small incision in the muscular layer of the left side of 
the bladder dome. As a control, 1 mm 3 pieces of normal bladder 
from syngeneic mice was transplanted similarly. 
To collect conditioned medium NUC-1 cells were grown in 
167 cm 2 culture flasks (Falcon, Lincoln Park, USA) to subconflu- 
ency in standard medium. The cells were then washed with PBS, 
incubated during one hour with serum-free medium, washed again 
with PBS, and finally incubated uring 24 or 48 h with 35 ml of 
serum-free medium. After collection, all media were filtered 
through a0.2 ~tm filter, and frozen at -20 ° C until use. 
Heat treatment ofmedium was carried out at 65 ° C for 30 min. 
Acid treatment was done with 1.0 M hydrochloric acid for 1 h, fol- 
lowed by neutralisation with 0.1 M sodium hydroxide. Reduction 
of medium components was performed with 0.1 M dithiothreitol 
(DTT, Boehringer, Almere, NL) for 1 h, followed by dialysis of 
the medium twice against serum-free medium, and a final filtra- 
tion through a 0.2 gm filter. Enzymatic digestion of medium pro- 
teins was done with 10 gg/ml trypsin for 1 h. The trypsin was in- 
activated by addition of 40 gg/ml trypsin inhibitor. Heparin-bind- 
ing capacity of the conditioned medium was tested by incubation 
with heparin-sepharose (Pharmacia, Woerden, NL) during 2 h at 
4 ° C. The medium was collected by centrifugation. The heparin- 
sepharose beads were washed firstly with water and subsequently 
treated with stepwise increases in the sodium chloride concentra- 
tion ranging from 0.15 M to 2.0 M. The eluted fractions were col- 
lected by centrifugation at 4 ° C after each treatment and tested for 
their ability to induce the proliferation ofg/G cells. 
Testing effects of growth factors on the proliferation of g/G 
cells was performed as previously described [7]. In brief, cells 
were first washed with PBS, then incubated uring 1 h in serum- 
free medium, washed again, and trypsinized. Fibronectin-precoat- 
ed wells in a 96-multiwell dish (NUNC, Roskilde, DK) were filled 
with 10000 viable cells per well in 150 gl serum-free medium. Af- 
ter 16 h, conditioned medium fractions to be tested were added 
(50 gl/well). After another 72 h, cultures were terminated. 
The presence of growth factors in NUC- 1 conditioned medium 
was assessed in bioassays with different cell lines. The prolifera- 
tion of these cell lines is modulated by specific growth factors un- 
der defined culture conditions [24]. The proliferation of ML- 
CCL64 and A431 cells is specifically inhibited by members of the 
TGFfl family and the EGF family, respectively. The proliferation 
of FBHE cells is specifically enhanced by members of the FGF 
family. 
Bioassays with ML-CCL64 cells, A431 cells, and FBHE cells 
were performed as described previously [24]. In brief, A431 cells 
were grown to subconfluency, rinsed with PBS, trypsinized, count- 
ed, and seeded at 2500 viable cells per well in a 96-multiwell dish 
in 150 gl/well DMEM medium with 5% FCS. After 16 h, 50 gl of 
fractions to be tested were added. Cells were then incubated for 
another 72 h. ML-CCL64 and FBHE cells were seeded at 5000 vi- 
able cells per well of a 24-well dish in 1 ml of DMEM with FCS 
(ML-CCL64) or without FCS (FBHE). After 3 h, 200 gl of the 
fractions that were to be tested, was added per well. Cells were 
then cultured for another 68 h. In experiments with neutralizing 
antibodies against TGF/J 1 or TGFfl2 (British Biotechnology, Ox- 
ford, GB) the fractions were pre-incubated with 2.0 gg of anti- 
body/ml medium at 37 ° C before addition to ML-CCL64 cells. 
Proliferation was assessed in vitro by [3H]-thymidine labelling 
using scintillation counting, and in vivo by bromodeoxyuridine 
(BrdU) labelling for the determination f the labelling index (L.I.) 
by immunocytochemistry. 
For assessing the proliferation i vitro, 0.5 gCi [3H]-thymidine 
per well was added 16 h before termination. Cells in 96-multiwell 
dishes were rinsed with PBS, trypsinized, and harvested. Tritiated 
thymidine was counted using a BetaPlate scintillation counter 
(Wallac-Pharmacia, Woerden, NL). Alternatively, cells in 24-wells 
dishes were rinsed with PBS, fixed with methanol, lysed in 0.1 M 
sodium hydroxide, and radioactivity in cell lysates was measured 
in a liquid ~, fl scintillation counter. Radioactivity was expressed 
as counts per minute. 
For assessing the proliferation i  vivo, mice were injected i.p. 
with bromodeoxyuridine (BrdU) in PBS (30 mg/kg body weight) 
1 h before sacrifice. Immunohistochemistry on paraffin-embedded 
tissue was performed as described previously [18], using the pri- 
mary anti-BrdU antibody IIB5 (kindly donated by Prof. Dr. F. C. 
S. Ramaekers, University of Limburg, Maastricht, NL). The L.I. 
was calculated as the relative number of BrdU positive cells per 
100 adjacent cells in the basal urothelial cell layer (normal) or 200 
adjacent cells in the first two basal cell layers (hyperplastic). The 
L.I. is given as the mean L.I+standard deviation. 
Results 
In vivo model 
After 1, 2, and 3 weeks, 5 mice were sacrificed and urine 
bladders were examined. No tumours were found in mice 
in which normal urine bladder was transplanted. The 
transplanted normal bladder had largely degenerated 
Fig. 1 Photomicrograph of 
haematoxylin-stained paraffin- 
embedded sections of (A) 
normal mouse urothelium and 
(B) a tumour of NUC-1 mouse 
urothelial cells 1 week after 
transplantation into the bladder 
submucosa of a syngeneic 
mouse. A Normal, non- 
hyperplastic urothelium 
adjacent to the region of 
degenerated, transplanted 
normal bladder. B Hyperplastic 
urothelium overlying the NUC- 
1 tumour, and non-hyperplastic 
urothelium at the opposed 
bladder wall. H, hyperplastic 
urothelium; N, normal urothel- 
ium; L, lumen of bladder; T, 




Table 1 Occurrence of hyperplasia in the in vivo transplantation 
model. In vivo data on transplanted tissue into bladder submucosa. 
The number of tumours in 5 animals is given at the indicated time 
interval after transplantation (weeks). The number of mice in 
which hyperplasia djacent o the tumour was observed, is also 
given, as well as the number of cell layers in the hyperplastic 
urothelium. The proliferation was expressed as the mean labelling 
index-+standard deviation (n=5) 
Weeks Tumours Hyperplasia Number of 
cell layers 
Labelling index (%) 
Hyperplastic Normal 
Transplanted NUC-I tumours 
1 5 5 
2 5 3 a 
3 5 4 b 
Transplanted normal bladder 
1 0 0 3 
2 0 0 3 
3 0 0 3 
6-10 9.6+5.6 0.7-+0.7 
5 20.7-+8.5 1.6-+0.1 




Overlying urothelium completely replaced by tumour an cells in 
a 2 out of 5 mice 
b 1 Out of 5 mice 
within one week. Hyperplasia of the urothelium was not 
noted (Fig. 1A) and BrdU incorporation was low in the 
overlying urothelium (Table 1). In contrast, at all three 
time intervals after transplantation of  NUC-1 tumour 
pieces, the urothelium overlying the transplants was hy- 
perplastic, with 5 or more cell layers (Fig. 1B). The hy- 
perplastic urothelium also showed high BrdU incorpora- 
tion, particularly in basal cell layers (Table 1). No nuclear 
atypia was noted in the hyperplastic urothelium. The uro- 
thelium lining the bladder lumen opposite to the hyper- 
plastic urothelium exhibited a normal appearance in 5 out 
of 5 mice after one week (Table 1), and showed a normal 
L.I. 
Chemico-physical nalysis and bioassays 
The next step was to find out if and which NUC-1 de- 
rived growth factors might be involved in the develop- 
ment of  hyperplasia. First, we examined whether NUC-1 
cells produced and secreted growth stimulatory factors. 
Therefore, a chemico-physical analysis of  serum-free 
conditioned medium of NUC- 1 cells was performed. The 
conditioned medium was tested in bioassays with g/G 
cells. As presented in Fig. 2A, conditioned medium of 
NUC-1 induced the proliferation of  g/G ceils, which 
could be inhibited by exogenous addition of TGFfll. 
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Fig. 2 [3H]-thymidine incorporation of g/G cells to (A) serum- 
free conditioned medium of NUC-1 cells and (B) growth factors in 
serum-free medium. A Proliferation in the presence of serum-free 
conditioned medium of NUC-1 with or without 1 ng/ml TGFfll, or 
pretreated under the indicated conditions. Incorporation i serum- 
free medium alone was taken as 100%. Tryp, trypsin-treated; heat, 
heat-treated; acid, acid-treated; DTT, DTT-treated; iq3=TGFfll. B 
Proliferation in the presence of the indicated growth factors alone 
(closed bars) or in the presence of 1 ng/ml TGFfll (open bars). In- 
corporation in serum-free medium alone was taken as 100%. 
Growth factor concentrations: 1 ng/ml (EGF, TGFc~, TGFfll) or 10 
ng/rnl (FGF-1, FGF-2) 
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Fig. 3 Bioassays with ML-CCL64, A431, FBHE, or g/G cells. A 
Incorporation of tritiated thymidine into the indicated cell lines in 
the presence of serum-free conditioned medium of NUC- 1 (CM), 
or in the presence of 0.88 ng/ml TGFfl] or TGFfl2 pretreated or 
not with antibody against TGFflt (Abl) or TGFfl2 (Ab2) (ML- 
CCL64 assay), 1 ng/ml EGF or TGFo~ (A431 assay), or 15 gg/ml 
ECGS (FBHE assay). Conditioned medium of NUC-1 cells was 
heat-pretreated before use in the bioassay with ML-CCL64 cells; 
for use in the other bioassays, the NUC-1 conditioned medium 
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are on the upper axis, and of FBHE cells on the lower axis. Incor- 
poration in the presence of non-conditioned serum-free medium 
alone was taken as 100%. ECGS (15 gg/ml) induced the prolifer- 
ation of FBHE cells approximately 20 times. B Incorporation of 
[3H]-thymidine into g/G cells in the presence of heparin-sepharo- 
se treated serum-free conditioned medium of NUC-1 cells frac- 
tionated with increasing salt concentrations. Final dilution of con- 
ditioned medium fractions as tested on g/G cells was 1:8. Incor- 
poration in the presence of serum-free medium alone (SF) was 
taken as 100% 
activity of  the NUC-1 derived condit ioned medium, and 
treatment with heat part ial ly reduced the enhanced pro- 
l iferation. Treatment with DTT only sl ightly affected the 
enhanced prol i feration of g/G cells. This sl ight decrease 
in prol i ferat ion might be due to the dialysis step fol low- 
ing DTT treatment. The results indicate that at least a 
DTT-stable polypept ide growth factor is present in the 
NUC-1 condit ioned medium. The sensit ivity to heat and 
acid treatment might indicate that the prol i feration in- 
ducing activity is a heat and acid labi le protein. Howev- 
er, the possibi l i ty that latent NUC-1 derived TGFf l  is ac- 
tivated upon heat or acid treatment, resulting in an inhi- 
bit ion of  prol i feration, cannot be excluded. 
Next, we investigated the effect of  different growth 
factors on prol i feration of  g/G cells under serum-free 
conditions. Figure 2B shows that EGF, TGFc~, FGF-1,  
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and FGF-2 could induce the proliferation of g/G cells. 
This growth factor induced proliferation could be inhibit- 
ed by addition of TGFfll. 
A further characterization f the proliferation-induc- 
ing activity was made using a series of growth factor 
specific bioassays. Bioassays with ML-CCL64 cells re- 
vealed TGFfl-like activity in NUC-1 derived condi- 
tioned medium that was heat-pretreated for activation 
of TGFfl, but this activity could not be neutralized by 
specific antibodies against TGFfll or TGFfl2, nor by 
combinations of these antibodies (Fig. 3A). Untreated 
NUC-1 conditioned medium was not active in the ML- 
CCL64 bioassay (data not shown). Bioassays with 
A431 indicated that the serum-free conditioned medium 
of NUC-1 cells did not contain detectable EGF-like 
growth factors (Fig. 3A). In particular, the resistance of 
DTT treatment excludes the involvement of growth fac- 
tors of which the biological activity is dependent on in- 
tact disulphide bonds. In order to test the possibility 
that the NUC-1 derived growth factor polypeptide was 
an FGF-like protein which is DTT stable, FGF-specific 
bioassays with FBHE cells were performed and the 
heparin-binding capacity was determined. Figure 3A 
shows that untreated conditioned medium of NUC-1 
stimulated the proliferation of FBHE cells by five 
times. If the conditioned medium of NUC- 1 was treated 
with heparin-sepharose, then washed with water, and 
subsequently eluted with increasing salt concentrations, 
the stimulatory protein was mainly contained in the 
0.15 M sodium chloride fraction (Fig. 3B). The first 
fraction which was eluted in the absence of salt, did not 
induce the proliferation (Fig. 3B). This indicates the 
presence of a protein in conditioned medium of NUC-1 
that binds specifically to heparin though with low affin- 
ity. Analysis of Western blots did not reveal any FGF- 
2-like molecule in NUC-1 conditioned medium. In line 
with this result, Northern blot analysis of poly A ÷ RNA 
from NUC-1 cells did not demonstrate d tectable FGF- 
2 expression. In addition, we failed to detect expression 
of FGF-1, FGF-3, and FGF-4 RNA in NUC-1 cells (da- 
ta not shown). 
Discussion 
Several studies on human transitional cell carcinomas 
(TCC) have revealed hyperplasia of the normal urotheli- 
um adjacent o the TCC [2, 11]. This hyperplasia has 
also been observed in experimentally induced urothelial 
carcinomas in the rat [12]. It has been suggested that this 
hyperplasia represented a precancerous stage in urotheli- 
um [11]. Similarly, several authors have considered hy- 
perplasia djacent to a colon carcinoma s a precancer- 
ous change [9, 16], an hypothesis disputed by Sekikawa 
et al. [19]. Using transplantations of colon carcinoma 
cells in mouse colon in vivo, they demonstrated altera- 
tions in mucin expression, morphology, and BrdU incor- 
poration in the mucosa overlying the turnout, but not in 
the remote mucosa or in their control animals transplant- 
ed with fibroblasts. They suggested an involvement of 
tumour-derived growth factors in the development of this 
hyperplasia. 
Our data demonstrated that only epithelium overlying 
the tumour was hyperplastic and showed a marked pro- 
liferation. Urothelium opposite or remote from the tu- 
mour, as well as urothelium of control transplanted mice 
did not show hyperplasia or significant proliferation. 
Bioassays with A431 cells, the lack of detectable TGF~ 
RNA and EGF protein expression in NUC-1 cells (data 
not shown), and the DTT stability excluded the identifi- 
cation of the NUC-l-derived, growth stimulatory protein 
as an EGF-like growth factor. Although bioassays with 
ML-CCL64 cells indicated that NUC-1 cells secreted a
TGFfl-like factor, this activity could not be neutralized 
by specific antibodies against TGFfl~ or TGFfl2. Howev- 
er, other members of the TGFfl family, like TGFfl3, 
could also be produced by NUC-1 cells. The data from 
Fig. 2A indicate that the NUC-1 stimulating activity dis- 
appears after heat or acid treatment of conditioned medi- 
um. This might be due to inactivation of the stimulatory 
protein, or to activation of TGFfl3. Because neutralizing 
antibodies against TGFfl3 were not available, we were 
unable to check for the presence of TGF]~ 3 in the NUC-1 
derived conditioned medium. The data of the bioassays 
with g/G cells indicated that the growth stimulating ef- 
fect of the NUC-l-derived factor can be inhibited by 
TGFfl, as is the case with the growth stimulating factors 
EGF and FGF (Fig. 2). The heparin-binding data indicate 
that the major fraction of growth stimulating factors 
binds heparin with low affinity. RNA analysis of NUC-1 
cells failed to detect FGF-1, FGF-2, FGF-3, and FGF-4. 
Of other FGFs, FGF-5 binds heparin with high affinity 
[25], and FGF-7 is a non-epithelial cell derived FGF [8]. 
These data may exclude the identification of oar growth 
stimulating factor as one of the classical FGFs. Little is 
known yet about FGF-6, FGF-8, and FGF-9 with respect 
to epithelial cells. 
Several data support he role of TCC-derived growth 
factors in hyperplastic development. Both TGF~ and 
FGF-like (FGF-1 or FGF-2) growth factors have been 
detected in the urine of patients with TCC [5, 6, 10]. 
Other studies have demonstrated an enhanced expression 
of FGF-1 proteins [17], FGF-5 RNA expression [25], 
and co-amplification f FGF-3 and FGF-4 genes [20] in 
human TCCs. Normal urine and urothelium contains 
EGF in high concentrations and only small amounts of 
FGF-1 or FGF-2 [3, 5, 6, 17]. The present study and pre- 
vious studies showed that these EGF-like and FGF-like 
growth factors could induce proliferation of non-tumori- 
genic transitional epithelial cells in vitro and in vivo [7, 
13]. Supporting evidence for the involvement of FGF- 
like factors in hyperplasia of epithelium was given by 
Muller et al. [15], who showed that expression of the 
FGF-3 gene in prostate or mammary gland epithelium of 
FGF-3 transgenic adult mice resulted in epithelial hyper- 
plasia in these organs. Hence, the observed hyperplasia 
of urothelium adjacent to TCC in vivo may be due to a 
direct, paracrine ffect of TCC-derived, FGF-like growth 
factors on the normal urothelial cells. However, we do 
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not know yet whether the NUC-1 derived factor is indeed 
FGF- l ike.  
Hyperp las ia  of  epi thel ium adjacent o pr imary carci-  
nomas has also been found in the oesophagus [4]. A 
striking f inding is that approximate ly  50% of all pr ima- 
ry oesophageal  carc inomas have a co-ampl i f icat ion of  
the FGF-3  and FGF-4  genes [21]. This indicates a more 
general  involvement of  FGF- l i ke  growth factors in the 
development of epithel ial  hyperplas ia  djacent o carci-  
nomas. 
In conclusion, in this study we obtained evidence for 
the induction of  hyperplasia of  urothel ium surrounding 
tumorigenic urothelial NUC-1 cells transplanted into the 
bladder wall. We also demonstrated that mouse tumori-  
genic urothel ial  NUC-1 cells produced and secreted a 
protein in vitro which was DTT stable, bound to heparin, 
and st imulated the prol i feration of  FBHE cells, which re- 
spond specif ical ly to FGFs.  The present data support the 
hypothesis that hyperplasia in bladder biopsies of  pa- 
tients with TCC does not necessari ly reflect a precancer-  
ous lesion prone to the development of  a new TCC. The 
observed hyperplasia may be due to tumour-der ived 
growth factors which have some chemico-physical  nd 
bio logical  propert ies of  FGFs.  A full characterizat ion of
the TCC-der ived growth st imulating factor(s) awaits fur- 
ther study. 
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